Gene Therapy - Table of Contents alert Volume 20 Issue 10

Advertisement We've always made the highest quality RNA, now we also make the best mRNA. GMP Manufacturing Affordable Custom Synthesis Genome Editing & Manipulation Tools Gene Replacement, Immunotherapy & Delivery Optimization Stocked Stem Cell Reprogramming Factors Contact us to discuss your path to pharmaceutical GMP manufacturing. www.trilinkbiotech.com/mRNA TABLE OF CONTENTS Volume 20, Issue 10 (October 2013) In this issue Mini Review Original Articles Short Communication Also new AOP Advertisement   Potential of Epigenetic Therapies in non-cancerous conditions Topic Editors: Steven G. Gray and Anne-Marie Baird ¦ Submission deadline: 31 Mar 2014 This Research Topic from Frontiers in Genetics aims to explore the evidence for and therapeutic potential of targeting the epigenome within non-cancerous settings. Find out more about how you can contribute to this RT or even host your own  Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Genes & Immunity celebrates its new Impact Factor - 3.872* Make an impact when you submit your paper to Genes & Immunity. Benefit from: - High exposure through Nature.com - Competitive turnaround times - Open access option - Inclusion in the leading abstracting and indexing services  Submit your research today. *2012 Journal Citation Reports® (Thomson Reuters, 2013)    Mini Review Top Current progress on gene therapy for primary immunodeficiencies L Zhang, A J Thrasher and H B Gaspar Gene Ther 2013 20: 963-969; advance online publication, May 30, 2013; 10.1038/gt.2013.21 Abstract | Full Text Original Articles Top Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency W Wang, Y Ma, J Li, H-S Shi, L-Q Wang, F-C Guo, J Zhang, D Li, B-H Mo, F Wen, T Liu, Y-T Liu, Y-S Wang and Y-Q Wei Gene Ther 2013 20: 970-978; advance online publication, May 2, 2013; 10.1038/gt.2013.19 Abstract | Full Text Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA OPEN Q-H Meng, S Irvine, A D Tagalakis, R J McAnulty, J R McEwan and S L Hart Gene Ther 2013 20: 979-986; advance online publication, May 2, 2013; 10.1038/gt.2013.20 Abstract | Full Text Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX OPEN Y Shi, R Falahati, J Zhang, L Flebbe-Rehwaldt and K M L Gaensler Gene Ther 2013 20: 987-996; advance online publication, June 13, 2013; 10.1038/gt.2013.22 Abstract | Full Text Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction S R Witting, P Vallanda and A L Gamble Gene Ther 2013 20: 997-1005; advance online publication, May 23, 2013; 10.1038/gt.2013.23 Abstract | Full Text MicroRNA-regulated non-viral vectors with improved tumor specificity in an orthotopic rat model of hepatocellular carcinoma J A Ronald, R Katzenberg, C H Nielsen, H J Jae, L V Hofmann and S S Gambhir Gene Ther 2013 20: 1006-1013; advance online publication, May 30, 2013; 10.1038/gt.2013.24 Abstract | Full Text Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy OPEN S Moimas, F Novati, G Ronchi, S Zacchigna, F Fregnan, L Zentilin, G Papa, M Giacca, S Geuna, I Perroteau, Z M Arnež and S Raimondo Gene Ther 2013 20: 1014-1021; advance online publication, May 30, 2013; 10.1038/gt.2013.26 Abstract | Full Text Short Communication Top 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy P Zarogoulidis, W Hohenforst-Schmidt, K Darwiche, L Krauss, D Sparopoulou, L Sakkas, A Gschwendtner, H Huang, F J Turner, L Freitag and K Zarogoulidis Gene Ther 2013 20: 1022-1028; advance online publication, May 30, 2013; 10.1038/gt.2013.27 Abstract | Full Text Advertisement Clinical & Translational Immunology Have you read this highly downloaded review article recently published in Clinical & Translational Immunology?  The delicate balance of melanoma immunotherapy  David E Gyorki, Margaret Callahan, Jedd D Wolchok and Charlotte E Ariyan  Browse and read more open access contents.  Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Gene Therapy. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.